No improvement seen in number of days alive and out of the hospital at 90 days for haloperidol versus placebo
Findings compared with both younger women and similarly aged men
No association seen between estimated R&D investments and treatment costs based on list prices at launch or net prices after one year
For 2018 compared with 2014, mean out-of-pocket cost of naloxone increased by 506 percent among uninsured patients
Under the law, Medicare will now be allowed to negotiate the cost of some drugs; vaccines will be free for Part D recipients
However, 86.6 percent of people with opioid use disorder are not receiving medication treatment
Meta-analyses suggest positive effects of noradrenergic drugs on global cognition, apathy
Increase in methadone-involved deaths in March 2020 not thought to be tied to expanded opioid treatment program take-home policies
Small pilot study suggests suvorexant may improve sleep, reduce opioid withdrawal and craving during buprenorphine/naloxone taper
Trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition